CN101168502A - 一种联苯乙酸氨丁三醇盐及其制备方法 - Google Patents
一种联苯乙酸氨丁三醇盐及其制备方法 Download PDFInfo
- Publication number
- CN101168502A CN101168502A CNA2006101430479A CN200610143047A CN101168502A CN 101168502 A CN101168502 A CN 101168502A CN A2006101430479 A CNA2006101430479 A CN A2006101430479A CN 200610143047 A CN200610143047 A CN 200610143047A CN 101168502 A CN101168502 A CN 101168502A
- Authority
- CN
- China
- Prior art keywords
- ammonia acetate
- preparation
- biphenyl ammonia
- felbinac
- trometamol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- GLTGDGIBGHPEKS-UHFFFAOYSA-N N.CC(O)=O.CCCC(O)(O)O.c1ccc(cc1)-c1ccccc1 Chemical compound N.CC(O)=O.CCCC(O)(O)O.c1ccc(cc1)-c1ccccc1 GLTGDGIBGHPEKS-UHFFFAOYSA-N 0.000 title claims description 47
- 238000006243 chemical reaction Methods 0.000 claims abstract description 24
- 229960000192 felbinac Drugs 0.000 claims abstract description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 15
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 12
- 230000000202 analgesic effect Effects 0.000 claims description 11
- 229960000281 trometamol Drugs 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 8
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 238000005352 clarification Methods 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 150000001298 alcohols Chemical group 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 abstract description 14
- 230000036407 pain Effects 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- -1 biphenylacetic acid tromethamine salt Chemical class 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 238000013461 design Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 abstract 1
- 230000005284 excitation Effects 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 238000012795 verification Methods 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 35
- 239000007924 injection Substances 0.000 description 35
- 239000007788 liquid Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000003462 vein Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 7
- 210000003205 muscle Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010002198 Anaphylactic reaction Diseases 0.000 description 6
- 230000036783 anaphylactic response Effects 0.000 description 6
- 208000003455 anaphylaxis Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 6
- 230000036285 pathological change Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000172 allergic effect Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 241000581650 Ivesia Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000026137 Soft tissue injury Diseases 0.000 description 2
- 208000004760 Tenosynovitis Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005261 decarburization Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001330002 Bambuseae Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008501 Cheyne-Stokes respiration Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241001615463 Trichogenes Species 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
溶剂 | 水 | 丙酮 | 甲醇 | 0.1mol/L氢氧化钠 | 甲酸 | 氯仿 |
溶解度ml/g* | 8.6 | 7.0 | 200 | 12.2 | 1200 | 11000 |
结论(药典规定ml/g) | 易溶,(1~10) | 易溶,(1~10) | 微溶(100~1000) | 易溶,(1~10) | 极微溶(1000~10000) | 不溶(10000以上) |
0正常 | 7呼吸急促 | 14步态不稳 |
1不安宁 | 8排尿 | 15跳跃 |
2立毛 | 9排粪 | 16喘息 |
3发抖 | 10流泪 | 17痉挛 |
4搔鼻 | 11呼吸困难 | 18横转 |
5喷嚏 | 12罗音 | 19潮式呼吸 |
6咳嗽 | 13紫癜 | 20死亡 |
0 | - | 过敏反应阴性 |
1-4症状 | + | 过敏反应弱阳性 |
1-10症状 | ++ | 过敏反应阳性 |
1-19症状 | +++ | 过敏反应强阳性 |
20 | ++++ | 过敏反应极强阳性 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006101430479A CN101168502B (zh) | 2006-10-23 | 2006-10-30 | 一种联苯乙酸氨丁三醇盐及其制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2006101229174A CN1944378A (zh) | 2006-10-23 | 2006-10-23 | 一种联苯乙酸氨丁三醇盐及其制备方法 |
CN200610122917.4 | 2006-10-23 | ||
CN2006101430479A CN101168502B (zh) | 2006-10-23 | 2006-10-30 | 一种联苯乙酸氨丁三醇盐及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101168502A true CN101168502A (zh) | 2008-04-30 |
CN101168502B CN101168502B (zh) | 2010-09-08 |
Family
ID=39389291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006101430479A Active CN101168502B (zh) | 2006-10-23 | 2006-10-30 | 一种联苯乙酸氨丁三醇盐及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101168502B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568300A (zh) * | 2018-12-11 | 2019-04-05 | 石家庄以岭药业股份有限公司 | 联苯乙酸或其盐在制备Xa抑制剂药物中的应用 |
-
2006
- 2006-10-30 CN CN2006101430479A patent/CN101168502B/zh active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109568300A (zh) * | 2018-12-11 | 2019-04-05 | 石家庄以岭药业股份有限公司 | 联苯乙酸或其盐在制备Xa抑制剂药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101168502B (zh) | 2010-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102753185B (zh) | 一种芒果苷小檗碱盐及其制备方法与用途 | |
US9724374B2 (en) | Capsule containing total flavonoids of desmodium styracifolium, method for preparing the same and use | |
US20170028007A1 (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
CN104086399A (zh) | 5-溴-2-(α-羟基戊基)苯甲酸钠盐的不同晶型及其制备方法 | |
CN102764426B (zh) | 一种蝎毒蛋白多肽的结肠靶向制剂及其制备方法 | |
CN107417556A (zh) | L‑天门冬氨酸螯合钙及其制备方法 | |
CN1944378A (zh) | 一种联苯乙酸氨丁三醇盐及其制备方法 | |
CN114191425A (zh) | 2,4-二羟基苯甲酸在治疗铁过载疾病食品药品中的应用 | |
CN101168502B (zh) | 一种联苯乙酸氨丁三醇盐及其制备方法 | |
CN103830170B (zh) | 伊维菌素在体凝胶注射剂及其制备方法 | |
CN101773475A (zh) | 一种辣椒碱微球的制备方法 | |
CN100475260C (zh) | 草豆蔻提取物及其制备 | |
CN102190644B (zh) | 手性3-羟基吡啶-4-酮类衍生物及其合成和用途 | |
CN101028336B (zh) | 一种头花蓼和独一味的药物组合物 | |
CN103284982A (zh) | 用于治疗癌症转移的方法和组合物 | |
CN102210787A (zh) | 紫花地丁总酚提取物治疗高尿酸血症的用途 | |
CN108567794B (zh) | 桃胶多糖在制备治疗或预防排尿不畅疾病的药物中的用途以及药物组合物 | |
CN109260217A (zh) | 3`-脱氧次黄嘌呤核苷在制备用于多种疾病药品、食品或保健品中的应用 | |
CN104107439B (zh) | 一种中药刺激性评价的检测方法 | |
CN101480400B (zh) | 雌酚酮类衍生物ea303的医药新用途 | |
CN102228696B (zh) | 聚乙二醇-聚乙烯醇共聚物-美他沙酮前药及其合成方法 | |
CN100408571C (zh) | 穿心莲内酯三马来酸半酯及其盐和它们的药物组合物 | |
CN102228427A (zh) | 一种牡荆素葡萄糖苷注射液及其制备方法 | |
CN1478774A (zh) | 穿心莲内酯三马来酸酯单钾盐和穿心莲内酯三马来酸酯三钾盐以及它们的药物组合物 | |
WO2012064221A1 (ru) | Средство для лечения поражений печени, вызванных воздействием химических или биологических агентов |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YILING PHARMACEUTICAL CO. LTD., SHIJIAZHUANG Free format text: FORMER OWNER: GUANGDONG ZHONGKE DRUG RESEARCH + DEVELOPMENT CO., LTD. Effective date: 20120724 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510630 GUANGZHOU, GUANGDONG PROVINCE TO: 050035 SHIJIAZHUANG, HEBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20120724 Address after: 050035 Shijiazhuang City, Hebei Province, Tianshan Road, No. 238 Patentee after: Shijiazhuang Yiling Pharmaceutical Co., Ltd. Address before: 510630, Guangdong, Zhongshan, Guangzhou Avenue, Tangxia, B Road, building on the four floor Patentee before: Guangdong Zonk Drug R & D Limited |
|
TR01 | Transfer of patent right |
Effective date of registration: 20191114 Address after: No.23, Keji Road, economic development zone, Miyun District, Beijing 101500 Patentee after: Beijing Yiling Biological Engineering Technology Co.,Ltd. Address before: 050035 No. 238 Tianshan Street, Hebei, Shijiazhuang Patentee before: Shijiazhuang Yiling Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210330 Address after: 050035 No. 238 Tianshan Avenue, Shijiazhuang hi tech Development Zone, Hebei, China Patentee after: Shijiazhuang Yiling Pharmaceutical Co.,Ltd. Address before: 101500 23 Keji Road, economic development zone, Miyun District, Beijing Patentee before: Beijing Yiling Bioengineering Co.,Ltd. |
|
TR01 | Transfer of patent right |